Medigen Vaccine Biologics (6547) - Total Assets
Based on the latest financial reports, Medigen Vaccine Biologics (6547) holds total assets worth NT$3.93 Billion TWD (≈ $123.94 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Medigen Vaccine Biologics (6547) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Medigen Vaccine Biologics - Total Assets Trend (2012–2025)
This chart illustrates how Medigen Vaccine Biologics's total assets have evolved over time, based on quarterly financial data. Check Medigen Vaccine Biologics earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Medigen Vaccine Biologics - Asset Composition Analysis
Current Asset Composition (December 2025)
Medigen Vaccine Biologics's total assets of NT$3.93 Billion consist of 60.1% current assets and 39.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 15.1% |
| Accounts Receivable | NT$130.02 Million | 3.3% |
| Inventory | NT$393.75 Million | 10.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$21.14 Million | 0.5% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Medigen Vaccine Biologics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Medigen Vaccine Biologics (6547) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medigen Vaccine Biologics's current assets represent 60.1% of total assets in 2025, an increase from 30.0% in 2012.
- Cash Position: Cash and equivalents constituted 15.1% of total assets in 2025, down from 26.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 65.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 10.0% of total assets.
Medigen Vaccine Biologics Competitors by Total Assets
Key competitors of Medigen Vaccine Biologics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Nanobiotix S.A
PA:NANO
|
France | €45.17 Million |
Medigen Vaccine Biologics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.77 | 11.94 | 7.58 |
| Quick Ratio | 10.64 | 9.83 | 7.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$2.18 Billion | NT$2.34 Billion | NT$1.69 Billion |
Medigen Vaccine Biologics - Advanced Valuation Insights
This section examines the relationship between Medigen Vaccine Biologics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.46 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -9.9% |
| Total Assets | NT$3.93 Billion |
| Market Capitalization | $472.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medigen Vaccine Biologics's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Medigen Vaccine Biologics's assets decreased by 9.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Medigen Vaccine Biologics (2012–2025)
The table below shows the annual total assets of Medigen Vaccine Biologics from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$3.93 Billion ≈ $123.94 Million |
-9.85% |
| 2024-12-31 | NT$4.36 Billion ≈ $137.49 Million |
-28.37% |
| 2023-12-31 | NT$6.09 Billion ≈ $191.95 Million |
-17.08% |
| 2022-12-31 | NT$7.35 Billion ≈ $231.49 Million |
+38.66% |
| 2021-12-31 | NT$5.30 Billion ≈ $166.95 Million |
+51.80% |
| 2020-12-31 | NT$3.49 Billion ≈ $109.98 Million |
+53.30% |
| 2019-12-31 | NT$2.28 Billion ≈ $71.74 Million |
+4.30% |
| 2018-12-31 | NT$2.18 Billion ≈ $68.78 Million |
+2.18% |
| 2017-12-31 | NT$2.14 Billion ≈ $67.31 Million |
+17.56% |
| 2016-12-31 | NT$1.82 Billion ≈ $57.26 Million |
+9.91% |
| 2015-12-31 | NT$1.65 Billion ≈ $52.09 Million |
+36.13% |
| 2014-12-31 | NT$1.21 Billion ≈ $38.27 Million |
+154.43% |
| 2013-12-31 | NT$477.40 Million ≈ $15.04 Million |
+217.95% |
| 2012-12-31 | NT$150.15 Million ≈ $4.73 Million |
-- |
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more